Abstract:The final, formatted version of the article will be published soon. You have multiple emails registered with Frontiers: Please enter your email address: If you already have an account, please login You don't have a Frontiers account ? You can register here Introduction: Antimicrobial-resistant pathogens are an ongoing threat to human and animal health.Colistin is considered the last resort antibiotic against human infections due to multidrug-resistant Gram-negative organisms, including Acinetobacter baumanni, a priority 1 pathogen according to the WHO. Despite colistin being a last resort, transferable bacterial resistance to this drug has been reported in humans and animals, making the need to tackle colistin resistance an essential path. The large PetN transferase membrane protein PmrC is the main responsible for colistin resistance, due to its catalysed modification of lipid A of the external membrane. Despite its importance, this potential drug target was never characterised at a molecular level.Methods: Recombinant production of large membrane proteins in their native forms is a bottleneck in modern molecular biology. We recombinantly produced PmrC and biophysically characterised it in solution. We employed in silico approaches, including virtual screening and molecular modelling, to identify PmrC ligands. Binding of these ligands to PmrC was measured using Microscale thermophoresis (MST). The best ligand was tested to its ability to hamper colistin resistance in A. baumannii clinical isolates. Finally, we checked that the identified compound is not cytotoxic at the used concentrations by haemolysis assays.We successfully produced PmrC PetN transferase membrane protein in high yields and showed that PmrC is a stable - protein, with melting temperature Tm=60°C. Based on PmrC structural model, we identified a promising druggable cavity. Therefore, we used a structure based virtual screening to identify potential inhibitors. A small molecule, here denominated as s-Phen, was proved to bind PmrC with μM affinity. Microbiological assays confirmed that the s-Phen can drastically reduce colistin MIC in two A. baumannii resistant isolates and that it is not cytotoxic.Importantly, PmrC binding pocket to s-Phen is highly conserved in all homologs of PmrC, regardless of the location of genes encoding for them and of their operons.Discussion: Our study provides a molecular characterisation of PmrC and demonstrates the importance of PmrC as a drug target and the strong potential of PmrC binding molecules to act as colistin adjuvants, operating as synergistic tools to combat multi-resistant nocosomial pathogens.

Dissecting the A-B personality type.

Cerastecins inhibit membrane lipooligosaccharide transport in drug-resistant Acinetobacter baumannii

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

Integrated computer-aided drug design and biophysical simulation approaches to determine natural anti-bacterial compounds for Acinetobacter baumannii

ETX2514 is a Broad-Spectrum Β-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-negative Bacteria Including Acinetobacter Baumannii

A novel antibiotic class targeting the lipopolysaccharide transporter

Repurposing FDA-approved drugs for combating tigecycline resistance in Acinetobacter baumannii: in silico screening against BaeR protein

Lacticaseibacillus rhamnosus CRL 2244 secreted metabolites display killing and antibiotic synergistic activity against multi-drug resistant pathogens

Synthesis and antibiofilm evaluation of N-acyl-2-aminopyrimidine derivatives against Acinetobacter baumannii

A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in Acinetobacter baumannii

Influence of Lipopolysaccharide-Interacting Peptides Fusion with Endolysin LysECD7 and Fatty Acid Derivatization on the Efficacy against Acinetobacter baumannii Infection In Vitro and In Vivo

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea

Unveiling MurE ligase potential inhibitors for treating multi-drug resistant Acinetobacter baumannii

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae

Virtual screening and biological activity evaluation of novel efflux pump inhibitors targeting AdeB

Structure-based targeting of the lipid A-modifying enzyme PmrC to contrast colistin resistance in Acinetobacter baumannii

Exploration of potential hit compounds targeting 1-deoxy-d-xylulose 5-phosphate reductoisomerase (IspC) from Acinetobacter baumannii: an in silico investigation

Interaction of Acinetobacter sp. RIT 592 induces the production of broad-spectrum antibiotics in Exiguobacterium sp. RIT 594

Targeting PilA in Acinetobacter baumannii: A Computational Approach for Anti-Virulent Compound Discovery

[Incomplete Garcin Syndrome of Hodgkin's Origin].

In vivo protein interaction network analysis reveals porin-localized antibiotic inactivation in Acinetobacter baumannii strain AB5075